The court ruled that Roche's claims are patent-ineligible because they are "directed to a natural phenomenon and lack any inventive concept" for a patent.
By early 2020, the UK company plans to develop a version of its Iona test that uses Illumina's sequencing technology.
The disagreement began when NuGen filed a lawsuit seeking a ruling of non-infringement of two of KeyGene's US patents related to next-generation sequencing.
The plaintiffs claim that Qiagen's QIAseq kits infringe Archer's US Patent No. 10,017,810, which covers parts of its Anchored Multiplex PCR (AMP) technology.
The lawsuit alleges Ancestry infringes 23andMe's method of matching relatives and damages its reputation via misleading online marketing.
Under the terms of the agreement, Oxford Nanopore Technologies will not sell its 2D sequencing products in the UK and in Germany for five years.
Reuters reports that the panel hearing the CRISPR gene editing patent case appears split.
KeyGene and its parent firm, KeyGene NV, were named as defendants in a NuGen Technologies suit seeking to invalidate two US patents.
The companies have been embroiled in several lawsuits in the US and in Europe, accusing each other of patent infringement.
NPR reports that with medical data being big business, some companies want to get patients involved.
The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.
In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.
Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.